SAN FRANCISCO, Feb. 24, 2014 (GLOBE NEWSWIRE) -- Amarantus Bioscience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that it has appointed Kerry Segal as Head of Business Development and Tiffini Clark as Head of Regulatory Affairs. Mr. Segal will be responsible for in-licensing and out-licensing activities, as well as merger and acquisition opportunities across therapeutics and diagnostics areas. Ms. Clark will be responsible for overseeing all regulatory activities, including support of business development activities.
"I am pleased to welcome Mr. Segal and Ms. Clark to Amarantus at this key time in our pipeline's life-cycle as we begin to evaluate business development opportunities for our current asset base, as well as review various product opportunities that have been presented to the Company," said Gerald E. Commissiong, President & CEO of Amarantus. "Successful transactions in the biopharmaceutical industry are achieved with proper preparation from a product development and regulatory standpoint, continued relationship building and experience in understanding the best strategic fit for both parties involved in discussions. We believe today's additions will build tremendous value to the Company as we continue on our path to build a world-class biotechnology company addressing the many unmet medical needs of patients around the world."
Mr. Segal is a 30-year veteran of the biopharmaceutical industry, including successful experiences while at Johnson & Johnson, Cephalon, Valeant, two start-ups and most recently Impax Pharmaceuticals. Mr. Segal's career encompasses 22 years of front-line transactional experience during which time he identified and closed transactions valued in excess of $2.6B and generated non-dilutive capital through partnerships in excess of $270M. Mr. Segal's forte is selectively identifying, pursuing, structuring and closing strategically prudent transactions that build shareholder value.
Ms. Clark brings over 20 years' experience to Amarantus, with over ten years of professional multidisciplinary biotech and pharmaceutical experience, primarily in regulatory, research and development. Ms. Clark recently served as Regulatory Affairs Specialist, Project Management & Regulatory Operations at Pharmacyclics. Previously, she served as Drug Safety Coordinator and Senior Archivist at Johnson & Johnson Pharmaceutical Research & Development. At Pharmacyclics, she was a team member that brought IBRUTINIB from discovery into Phase 3 clinical development and was an integral member of the business development team that executed $975M BTK transaction with Janssen Biotech, Inc. (IBRUTINIB). Ms. Clark was also an integral member of the business development team that completed transactions with Novo Nordisk for the Factor VIIa inhibitor, PCI-27483, and the pan-HDAC deal with Les Laboratories Servier (ABEXINOSTAT). Ms Clark has prepared, submitted and maintained 7 IND's, 1 NDA, several Orphan Drug Applications, FDA meeting packages and Fast Track designations.
About Amarantus
Amarantus is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis. The Company has licensed Eltoprazine ("Eltoprazine"), a phase 2b ready indication for Parkinson's Levodopa induced dyskinesia and Adult ADHD. The Company has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test®") for Alzheimer's disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. Amarantus is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. The Company also owns intellectual property for the diagnosis of Parkinson's disease ("NuroPro") and the discovery of neurotrophic factors ("PhenoGuard"). For further information please visit www.Amarantus.com , or connect with the Company on Facebook , LinkedIn , Twitter and Google+ .
Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are forward-looking statements. These forward-looking statements generally are identified by the words "believes," "project," "expects," "anticipates," "estimates," "intends," "strategy," "plan," "may," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.
Investor/Media Contacts Aimee Boutcher, Director of Investor Relations Amarantus Bioscience Holdings, Inc. 408-737-2734 x 101
